throbber
10/7/2015 Experience with the use of an iron polymaltose (dextrin) complex given by single total dose infusion to stable chronic haemodialysis patients. ­ Google Sc…
`
`Experience with the use of an iron polymaltose (dextrin) complex given by single total dose
`infusion to stable chronic haemodialysis patients
`R van Zyl­Smit, JA Halkett ­ Nephron, 2002 ­ karger.com
`Background: Many studies of anaemia in patients on chronic haemodialysis have noted a 
`high prevalence of iron deficiency despite oral iron supplementation. Our study examined 
`the effect of intravenous iron given as bolus replacement. As the majority of these patients ...
`Cited by 6  Related articles  All 5 versions  Cite  Save
`
`Showing the best result for this search. See all results
`
`https://scholar.google.com/scholar?hl=en&q=Experience+with+the+use+of+an+iron+polymaltose+%28dextrin%29+complex+given+by+single+total+dose+in… 1/2
`
`Luitpold Pharmaceuticals, Inc., Ex. 2025, p.1
`
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01495
`
`

`
`10/7/2015 Experience with the use of an iron polymaltose (dextrin) complex given by single total dose infusion to stable chronic haemodialysis patients. ­ Google Sc…
`
`https://scholar.google.com/scholar?hl=en&q=Experience+with+the+use+of+an+iron+polymaltose+%28dextrin%29+complex+given+by+single+total+dose+in… 2/2
`
`Luitpold Pharmaceuticals, Inc., Ex. 2025, p.2
`
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01495
`
`

`
`10/7/2015
`
`van Zyl­Smit: Experience with the use of an iron... ­ Google Scholar
`
`Association between transferrin receptor–ferritin index and conventional measures of iron
`responsiveness in hemodialysis patients
`YC Chen, SC Hung, DC Tarng ­ American journal of kidney diseases, 2006 ­ Elsevier
`Background: The diagnostic power of the transferrin receptor–ferritin (TfR­F) index for 
`identification of iron responsiveness in long­term hemodialysis (HD) patients compared with 
`the routine markers recommended by the current US and European guidelines was ...
`Cited by 32  Related articles  All 8 versions  Cite  Save
`Management of iron deficiency in patients admitted to hospital: time for a rethink of treatment
`principles
`I Ahmad, PR Gibson ­ Internal medicine journal, 2006 ­ Wiley Online Library
`Background: Iron deficiency is very common in patients admitted to hospital. Its management 
`is changing with new insights into iron absorption and therapeutic options. Aims: The aims of 
`this study were to develop guidelines for the correction of iron deficiency in patients ...
`Cited by 18  Related articles  All 7 versions  Cite  Save
`
`静脉用右旋糖酐氢氧化铁注射液治疗肾性贫血疗效观察
`李德天, 李旭, 王艳秋, 刘大军, 杨旭, 周光宇… ­ 中国实用内科 …, 2005 ­ tuliao86.com
`[摘要] 目的观察大剂量静脉给予右旋糖酐氢氧化铁注射液(科莫非) 治疗慢性肾衰患者铁缺乏的
`有效性与安全性. 方法对2004—01~ 2005—02 中国医科大学第二临床学院肾内科46 
`例患者根据公式计算总补铁量, 应用科莫非进行补铁治疗. 于用药前及首次用药后2 周, 停药后 ...
`Cited by 20  Related articles  All 9 versions  Cite  Save  More
`
`蔗糖铁联合重组人红细胞生成素改善血液透析患者中度贫血的临床观察
`潘金林, 石春晖, 岳菊三, 吴耀偿 ­ 中国医学创新, 2013 ­ cqvip.com
`目的: 观察静脉用蔗糖铁联合重组人促红细胞生成素(erythropoietin, EPO) 
`对维持性血液透析患者中度贫血的疗效及不良反应. 方法: 选取2011 年1 月­2012 年12 
`月本院收治的维持性血液透析中度贫血患者52 例, 给予静脉滴注蔗糖铁和重组人红细胞生成 ...
`Cited by 3  Related articles  All 3 versions  Cite  Save
`
`静脉注射右旋糖酐铁治疗腹透患者肾性贫血的应用价值
`赵占正, 肖静, 程根阳, 王沛, 刘章锁 ­ 中国误诊学杂志, 2005 ­ cqvip.com
`目的: 观察静脉注射右旋糖酐氢氧化铁治疗连续性不卧床腹膜透析(CAPD) 
`的慢性肾衰患者铁缺乏的有效性与安全性. 方法: 采用静脉注射右旋糖酐氢氧化铁和琥珀酸亚铁
`口服补铁, 观察血红蛋白(Hb), 红细胞压积(Hct), 血清铁蛋白(SF), 转铁蛋白饱和度(TS) 及肝肾 ...
`Related articles  All 5 versions  Cite  Save
`
`右旋糖酐铁治疗血液透析患者重度肾性贫血
`程晖, 张丽丽, 杨定平 ­ 中国药师, 2006 ­ cqvip.com
`目的: 观察右旋糖酐铁注射液治疗维持性血液透析(血透) 患者肾性贫血的疗效. 方法: 46 
`例维持性血透患者, 每周血液透析3 次, 每次4h. 随机分为注射右旋糖酐氢氧化铁组(21 例) 
`与口服琥珀酸亚铁组(25 例), 检测治疗前后血清铁指标, 红细胞相关指标及生化指标. 结果: 10 ...
`Related articles  All 5 versions  Cite  Save
`
`https://scholar.google.com/scholar?cites=15084575114737782288&as_sdt=400005&sciodt=0,14&hl=en
`
`1/2
`
`Luitpold Pharmaceuticals, Inc., Ex. 2025, p.3
`
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01495
`
`

`
`10/7/2015
`
`van Zyl­Smit: Experience with the use of an iron... ­ Google Scholar
`
`https://scholar.google.com/scholar?cites=15084575114737782288&as_sdt=400005&sciodt=0,14&hl=en
`
`2/2
`
`Luitpold Pharmaceuticals, Inc., Ex. 2025, p.4
`
`Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., IPR2015-01495

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket